Pulmonary granulomas after tumour necrosis factor alpha antagonist therapy.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 12612312.
- Also identified by PMC identifier 1746601.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Tumour necrosis factor alpha (TNFalpha) antagonists are an established therapeutic option in Crohn's disease and rheumatoid arthritis. In recently published studies these agents have been used with great success, but little is known about any side effects or long term consequences. They increase the frequency of infections with mycobacteria, where TNFalpha is thought to be an important host defence factor. We describe one patient who was treated with TNFalpha antagonists and later developed pulmonary granulomas with caseating necrosis without detection of mycobacteria or any other pathogens. Possible mechanisms involved in this newly recognised side effect are discussed.
Medical subject headings
- Antibodies, Monoclonal
- Antirheumatic Agents
- Arthritis, Rheumatoid
- Pulmonary Fibrosis